91 related articles for article (PubMed ID: 28939971)
1. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
Janovick JA; Spicer TP; Bannister TD; Scampavia L; Conn PM
PLoS One; 2017; 12(8):e0181830. PubMed ID: 28767678
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants.
Kuramoto R; Kise R; Kanno M; Kawakami K; Ikuta T; Makita N; Inoue A
PLoS One; 2024; 19(5):e0303507. PubMed ID: 38748623
[TBL] [Abstract][Full Text] [Related]
3. Chaperoning G protein-coupled receptors: from cell biology to therapeutics.
Tao YX; Conn PM
Endocr Rev; 2014 Aug; 35(4):602-47. PubMed ID: 24661201
[TBL] [Abstract][Full Text] [Related]
4. Emerging novel concept of chaperone therapies for protein misfolding diseases.
Suzuki Y
Proc Jpn Acad Ser B Phys Biol Sci; 2014; 90(5):145-62. PubMed ID: 24814990
[TBL] [Abstract][Full Text] [Related]
5. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.
Naik S; Zhang N; Gao P; Fisher MT
Curr Top Med Chem; 2012; 12(22):2504-22. PubMed ID: 23339304
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor.
Janovick JA; Patny A; Mosley R; Goulet MT; Altman MD; Rush TS; Cornea A; Conn PM
Mol Endocrinol; 2009 Feb; 23(2):157-68. PubMed ID: 19095769
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Chaperones: Beyond Conformational Disorders.
Leidenheimer NJ
Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
[TBL] [Abstract][Full Text] [Related]
8. Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria.
Majtan T; Pey AL; Gimenez-Mascarell P; Martínez-Cruz LA; Szabo C; Kožich V; Kraus JP
Handb Exp Pharmacol; 2018; 245():345-383. PubMed ID: 29119254
[TBL] [Abstract][Full Text] [Related]
9. Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.
Marinko JT; Huang H; Penn WD; Capra JA; Schlebach JP; Sanders CR
Chem Rev; 2019 May; 119(9):5537-5606. PubMed ID: 30608666
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
11. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
Mouillac B; Mendre C
Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
[TBL] [Abstract][Full Text] [Related]
13. Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.
Mendre C; Mouillac B
Adv Protein Chem Struct Biol; 2019; 118():249-272. PubMed ID: 31928727
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
Mouillac B; Mendre C
Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
[TBL] [Abstract][Full Text] [Related]
15. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.
Jean-Alphonse F; Perkovska S; Frantz MC; Durroux T; Méjean C; Morin D; Loison S; Bonnet D; Hibert M; Mouillac B; Mendre C
J Am Soc Nephrol; 2009 Oct; 20(10):2190-203. PubMed ID: 19729439
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
